DDInter655 DDInter178
An anthracycline which is the 4&#39;-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Epirubicin {u} (Compound) treats {v} (Disease) ovarian cancer
Epirubicin {u} (Compound) binds {v} (Gene) YWHAG
Epirubicin {u} (Compound) upregulates {v} (Gene) SCPEP1
Epirubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Epirubicin {u} (Compound) downregulates {v} (Gene) KPNA2
Epirubicin {u} (Compound) causes {v} (Side Effect) Haemoptysis
Epirubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Epirubicin (Compound) resembles Doxorubicin (Compound)
Epirubicin (Compound) resembles Valrubicin (Compound)
Epirubicin (Compound) treats ovarian cancer (Disease)
Epirubicin (Compound) binds YWHAG (Gene)
Epirubicin (Compound) upregulates SCPEP1 (Gene)
Epirubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Epirubicin (Compound) downregulates KPNA2 (Gene)
Epirubicin (Compound) causes Haemoptysis (Side Effect)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin